NO951306L - Antisens oligonukleotidinhibisjon av ras genet - Google Patents

Antisens oligonukleotidinhibisjon av ras genet

Info

Publication number
NO951306L
NO951306L NO951306A NO951306A NO951306L NO 951306 L NO951306 L NO 951306L NO 951306 A NO951306 A NO 951306A NO 951306 A NO951306 A NO 951306A NO 951306 L NO951306 L NO 951306L
Authority
NO
Norway
Prior art keywords
ras
oligonucleotides
ras gene
human
gene
Prior art date
Application number
NO951306A
Other languages
English (en)
Norwegian (no)
Other versions
NO951306D0 (no
Inventor
Brett P Monia
Susan M Freier
David J Ecker
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/009346 external-priority patent/WO1994008003A1/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of NO951306D0 publication Critical patent/NO951306D0/no
Publication of NO951306L publication Critical patent/NO951306L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/125—Modifications characterised by incorporating agents resulting in resistance to degradation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO951306A 1992-10-05 1995-04-04 Antisens oligonukleotidinhibisjon av ras genet NO951306L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95813492A 1992-10-05 1992-10-05
US799693A 1993-01-21 1993-01-21
PCT/US1993/009346 WO1994008003A1 (en) 1991-06-14 1993-10-01 ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE

Publications (2)

Publication Number Publication Date
NO951306D0 NO951306D0 (no) 1995-04-04
NO951306L true NO951306L (no) 1995-04-04

Family

ID=26677617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951306A NO951306L (no) 1992-10-05 1995-04-04 Antisens oligonukleotidinhibisjon av ras genet

Country Status (11)

Country Link
US (1) US6117848A (ja)
EP (1) EP0670897A4 (ja)
JP (1) JP2739769B2 (ja)
KR (1) KR100199247B1 (ja)
AU (1) AU680449B2 (ja)
CA (1) CA2146320C (ja)
FI (1) FI951601A7 (ja)
HU (1) HUT73335A (ja)
IL (1) IL107198A0 (ja)
NO (1) NO951306L (ja)
NZ (1) NZ256974A (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
AU5333298A (en) 1996-12-27 1998-07-31 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US20020119570A1 (en) * 2000-09-25 2002-08-29 Kyonggeun Yoon Targeted gene correction by single-stranded oligodeoxynucleotides
US20020165196A1 (en) * 2001-05-07 2002-11-07 Eric Wickstrom Oligonucleotide inhibitors of cancer cell proliferation
US20030054354A1 (en) * 2001-08-23 2003-03-20 Bennett C. Frank Use of antisense oligonucleotide libraries for identifying gene function
US8460864B2 (en) * 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
WO2006050732A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
US8927598B2 (en) * 2008-01-30 2015-01-06 Duke University Treating oncogenic Ras driven cancers
MX2018000412A (es) * 2015-07-10 2018-03-14 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
PH12018501207B1 (en) * 2015-12-21 2024-02-23 Novartis Ag Compositions and methods for decreasing tau expression

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
PT85446A (pt) * 1986-07-31 1988-07-29 Yelverton Williams Patrick Porca de seguranca
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5623065A (en) * 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
ATE186072T1 (de) * 1991-06-14 1999-11-15 Isis Pharmaceuticals Inc Antisense-oligonukleotid-inhibition des ras-gen
US5582986A (en) * 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
JP3131222B2 (ja) * 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する２′修飾オリゴヌクレオチド
FR2705099B1 (fr) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.

Also Published As

Publication number Publication date
NO951306D0 (no) 1995-04-04
EP0670897A4 (en) 1997-08-06
HU9500979D0 (en) 1995-06-28
US6117848A (en) 2000-09-12
JPH07508657A (ja) 1995-09-28
EP0670897A1 (en) 1995-09-13
FI951601A0 (fi) 1995-04-04
FI951601L (fi) 1995-05-29
NZ256974A (en) 1997-12-19
KR100199247B1 (ko) 1999-06-15
FI951601A7 (fi) 1995-05-29
AU680449B2 (en) 1997-07-31
JP2739769B2 (ja) 1998-04-15
HUT73335A (en) 1996-07-29
CA2146320A1 (en) 1994-04-14
IL107198A0 (en) 1994-01-25
CA2146320C (en) 2004-12-14
AU5295993A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
CA2296535A1 (en) Antisense oligonucleotide inhibition of ras
NO951306L (no) Antisens oligonukleotidinhibisjon av ras genet
Spencer et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas
Esler et al. Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder
Melkonyan et al. Transrenal Nucleic Acids: From Proof of Principle to Clinical Tests: Problems and Solutions
Durkin et al. Replication stress induces tumor-like microdeletions in FHIT/FRA3B
Tien et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation
US8785414B2 (en) Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
Merriwether et al. The four founding lineage hypothesis for the New World: a critical reevaluation
NO965080L (no) Antisens oligonukleotidmodulering av genekspresjon
BR9206156A (pt) Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS
US20160076098A1 (en) Methods of diagnosing and treating chronic pain
CN109890983A (zh) 用于评估免疫应答的组合物和方法
Amiguet‐Vercher et al. Loss of the mono‐allelic control of the VSG expression sites during the development of Trypanosoma brucei in the bloodstream
Bailly et al. The influence of the 2‐amino group of guanine on DNA conformation. Uranyl and DNase I probing of inosine/diaminopurine substituted DNA.
Tomasz et al. The purine 2-amino group as the critical recognition element for sequence-specific alkylation and cross-linking of DNA by mitomycin C
Holley et al. Evidence for the liberation of a nuclease from human fingers
WO1992019770A3 (en) Process for the in vitro diagnosis of chromosomal anomalies correlated with cmt1a disease
Rao et al. DNA Polymerase‐β May Be the Main Player for Defective DNA Repair in Aging Rat Neurons
Wulf et al. Renin in acute myeloid leukaemia blasts
Snydert et al. Studies on the inhibition of repair of ultraviolet-and methyl methanesaHonate-indnced damage in the DNA of human fibrobhsts by novobiocin
Rykova et al. Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood
Galbiati et al. Different approaches for noninvasive prenatal diagnosis of genetic diseases based on PNA‐mediated enriched PCR
Kaplan et al. Initiation and transcription of a set of transfer ribonucleic acid genes in vitro.
Chiba Radiation-responsive transcriptome analysis in human lymphoid cells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application